Ross Moat - Apr 1, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Apr 1, 2023
Transactions value $
$0
Form type
4
Date filed
4/3/2023, 04:30 PM
Previous filing
Mar 20, 2023
Next filing
Apr 11, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +38.7K $0.00 38.7K Apr 1, 2023 Class A Common Share 38.7K $10.76 Direct F1
transaction KNSA Restricted Share Unit Award $0 +6.45K $0.00 6.45K Apr 1, 2023 Class A Common Share 6.45K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.
F2 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F3 The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023.